Clinical outcomes of left atrial appendage occlusion in patients with previous intracranial or gastrointestinal bleeding: Insights from the LOGIC (Left atrial appendage Occlusion in patients with Gastrointestinal or IntraCranial bleeding) International Multicenter Registry.
antithrombotic therapy
gastrointestinal bleeding
intracranial bleeding
left atrial appendage occlusion
oral anticoagulation
stroke
Journal
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
ISSN: 1522-726X
Titre abrégé: Catheter Cardiovasc Interv
Pays: United States
ID NLM: 100884139
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
revised:
30
01
2023
received:
26
11
2022
accepted:
03
03
2023
medline:
11
5
2023
pubmed:
17
3
2023
entrez:
16
3
2023
Statut:
ppublish
Résumé
To compare outcomes of patients who underwent left atrial appendage occlusion (LAAO) for nonvalvular atrial fibrillation (NVAF) and contraindication to anticoagulants due to history of either gastrointestinal (GI) or intracranial (IC) bleeding. Patients with NVAF that underwent LAAO for GI or IC bleeding from seven centers were included in this observational study. Baseline characteristics, procedural features, and follow-up data were collected, and compared between the two groups. The primary outcomes were incidence of ischemic and hemorrhagic events at 12-month. Six hundred twenty-eight patients were included, 57% with previous GI-bleeding, and 43% with previous IC-bleeding. Median CHA 2 DS 2-VASc score was 4 (interquartile range [IQRs]: 3-5) for both GI-bleeding and IC-bleeding patients, while GI-bleeding patients had a higher HAS-BLED score (4 [IQRs: 3-4] vs. 3 [IQRs]: 2-3]; p = 0.001). At 12-month follow-up, relative risk reduction for stroke was similar between the two groups. The GI-bleeding group had more hemorrhagic events compared to IC-bleeding group (any bleeding 8.4% vs. 3.2%; p = 0.012; major bleeding BARC 3-5: 4.3% vs. 1.8; p = 0.010). At multivariate analysis history of GI bleeding was an independent predictor of hemorrhagic events (adjusted HR: 2.39, 95% confidence interval: 1.02-5.63; p = 0.047). Outcomes after LAAO may be affected by the different indications for the procedure. In our study, GI-bleeding and IC-bleeding as indication to LAAO differ in their baseline characteristics. LAAO confirms its efficacy in ischemic risk reduction in both groups, while GI bleeding seems to be an independent predictor of bleeding recurrence at 12 months behind the antithrombotic regimen.
Types de publication
Observational Study
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1144-1153Informations de copyright
© 2023 Wiley Periodicals LLC.
Références
Landmesser U, Tondo C, Camm J, et al. Left atrial appendage occlusion with the AMPLATZER amulet device: one-year follow-up from the prospective global amulet observational registry. EuroIntervention. 2018;14:e590-e597.
Freeman Jv, Varosy P, Price MJ, et al. The NCDR left atrial appendage occlusion registry. JACC. 2020;75:1503-1518.
Aminian A, de Backer O, Nielsen-Kudsk JE, et al. Incidence and clinical impact of major bleeding following left atrial appendage occlusion: insights from the amplatzer amulet observational post-market study. EuroIntervention. 2021;17:774-782.
Casu G, D'Angelo G, Ugo F, et al. Left atrial appendage occlusion in atrial fibrillation patients with previous intracranial bleeding: a national multicenter study. Int J Cardiol. 2021;328:75-80.
Pouru JP, Lund J, Jaakkola S, et al. Percutaneous left atrial appendage closure in patients with prior intracranial bleeding and thromboembolism. Heart Rhythm. 2020;17:915-921.
Glikson M, Wolff R, Hindricks G, et al. EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion-an update. EP Europace. 2020;22:184.
Lempereur M, Aminian A, Freixa X, et al. Left atrial appendage occlusion in patients with atrial fibrillation and previous major gastrointestinal bleeding (from the Amplatzer Cardiac Plug Multicenter Registry). Am J Cardiol. 2017;120:414-420.
Tarantini G, D'Amico G, Schmidt B, et al. The impact of CHA2DS2-VASc and HAS-BLED scores on clinical outcomes in the amplatzer amulet study. JACC: Cardiovasc Interv. 2020;13:2099-2108.
Tzikas A, Freixa X, Llull L, et al. Patients with intracranial bleeding and atrial fibrillation treated with left atrial appendage occlusion: results from the amplatzer cardiac plug registry. Int J Cardiol. 2017;236:232-236.
Donal E, Lip GYH, Galderisi M, et al. EACVI/EHRA expert consensus document on the role of multi-modality imaging for the evaluation of patients with atrial fibrillation. Eur Heart J Cardiovasc Imag. 2016;17:355-383.
Saw J, Lempereur M. Percutaneous left atrial appendage closure. JACC: Cardiovasc Interv. 2014;7:1205-1220.
Mehran R, Rao Sv, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials. Circulation. 2011;123:2736-2747.
Tzikas A, Holmes DR Jr., Gafoor S, et al. Percutaneous left atrial appendage occlusion: the Munich consensus document on definitions, endpoints, and data collection requirements for clinical studies. Europace. 2017;19:4-15.
Friberg L, Rosenqvist M, Lip GYH. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish atrial fibrillation cohort study. Eur Heart J. 2012;33:1500-1510.
Lip GY, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. JACC. 2011;57:173-180.
Boersma Lv, Ince H, Kische S, et al. Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-year follow-up outcome data of the EVOLUTION trial. Heart Rhythm. 2017;14:1302-1308.
Busu T, Khan SU, Alhajji M, Alqahtani F, Holmes DR, Alkhouli M. Observed versus expected ischemic and bleeding events following left atrial appendage occlusion. Am J Cardiol. 2020;125:1644-1650.
Reddy VY, Doshi SK, Kar S, et al. 5-Year outcomes after left atrial appendage closure. JACC. 2017;70:2964-2975.
della Rocca DG, Magnocavallo M, di Biase L, et al. Half-dose direct oral anticoagulation versus standard antithrombotic therapy after left atrial appendage occlusion. JACC: Cardiovasc Interv. 2021;14:2353-2364.